Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Information about patients' preference must be obtained first
EDITOR It is important to consider the bases of these preferences,
particularly as there is a widespread and unsupported belief that new
treatments are likely to be superior to existing
alternatives.2 For example, it seems that people with
diabetes who were being recruited to a randomised comparison of insulin
pumps with conventional management were left with the impression that
pumps represented an important advance (C Bradley, personal
communication). Not surprisingly, therefore, those allocated to pumps
were pleased, while those allocated to conventional management were
disappointed. Randomisation thus created comparison groups that were
incomparable in these psychological characteristics, and this may have
had implications for compliance and evaluation of treatment
outcome.3
Bradley's response3 was to propose the partially
randomised patient preference design to which Torgerson and Sibbald
refer. Unfortunately, this does not help because it cannot distinguish
between an effect of preferences and an effect of confounding of
preferences with prognosis. Since it is impossible to randomise between
sincerely held preferences, measuring their effects reliably requires a
more complicated design, which was suggested originally by
Rucker4 and recently discussed by McPherson et
al.5 In this design, people are randomised between either
a randomised comparison or a preference comparison.
Genuine therapeutic effects may, however, be associated with
preferences, over and above those related to adherence to treatment.
Several blind trials show an advantage associated with adherence to
placebo.5 Obtaining hard evidence on possible preference
effects is problematic as it is difficult to distinguish reliably
between simple therapeutic effects and preference effects mediated
through psychological pathways in experiments.
There are thus two areas that need attention. Firstly, there needs to
be wider acknowledgement that preferences for treatments should be
based on beliefs that are founded on reliable information. This should
help to increase the proportion of well informed people who have no
strong preferences and would thus be eligible to participate in
comparisons between randomised treatments. Secondly, studies are
required to enable a rigorous distinction to be made between simple
therapeutic effects and preference effects. This means that well
accepted biological hypotheses will be needed for adequate recruitment,
and a plausible biological model to distinguish the two kinds of
effect. As Torgerson and Sibbald suggest, however, the first step is
routinely to elicit information about the preferences of well informed
patients.
Merits of alternative strategies for incorporating patient
preferences into clinical trials must be considered carefully
EDITOR We stratified our two groups
Our main overall finding of greater dissatisfaction in the new style
group applies only to those who had either an initial preference for
traditional care or no initial preference. When women had an initial
preference for new style care the effect was in the opposite direction.
Similarly, the finding that women in the new style group had a more
negative attitude to their fetuses only applies to those who initially
preferred traditional care or had no initial preference. This analysis
provides information that is relevant for new policies: women with an
active preference for fewer visits should not be denied this option
because of concern about possible detrimental psychosocial effects.
A partially randomised patient preference design would have yielded
similar findings, but at the cost of a substantial increase in sample
size. We assumed that all those with an initial preference would have
opted for their preferred type of care and that eligible women who
declined participation because they did not want to have fewer
antenatal visits would have taken part if it had been a preference
trial. We calculate that the required overall sample size would have
increased from 2830 to 7989. This highlights the need to consider
carefully the respective merits of alternative strategies for
incorporating patient preferences into clinical trials.
Authors' reply
EDITOR Clearly it is important that patients are given reliable information.
It is, however, likely that some patients have preferences and are
still prepared to be randomised. What should be done with such
patients? Including them in a "partially randomised preference
trial" is unsatisfactory, as McPherson and Chalmers state.
Randomising patients between a fully randomised design and a preference
trial is problematic, as suggested, not least because those patients
allocated to a fully randomised design must be denied their preferences
if full assessment of preferences is to be taken into account. This is
probably ethical if the preferred treatment is available only to
randomised patients.
Randomising all consenting patients and eliciting their treatment
preferences may help.2 Clement et al show that this is
both feasible and a better alternative to the partially randomised
design. They are, however, incorrect to assume that a partially
randomised patient preference trial would have yielded similar
findings. The preference arms in a preference trial could have been
subject to confounding and, furthermore, would not have yielded
information on the dissatisfaction rates and attitude scores of women
allocated to their unpreferred treatment.
The importance of this is illustrated in the findings of their previous
paper. The odds ratio of dissatisfaction was 2.50 (95% confidence
interval 2.00 to 3.11) for the new group compared with the traditional
group.3 When all women with an initial preference are
removed (hence achieving a balance of preference between the two
groups) the odds ratio increases to 5.62 (3.61 to 8.94), thus
indicating a significant effect of preference on this trial outcome.
McPherson et al point out the sample size required to test for any
interaction between preference and outcome would need to be relatively
large.4 Many trials may be too small to examine the
interaction between preference and outcome. One solution may be to try
to standardise how preferences are elicited and then use
meta-analytical techniques by combining a number of trials to assess
differences in outcome by preference.
Torgerson and Sibbald discuss the difficulties of assessing the
relative merits of treatments when patients have strong preferences for
one of the alternatives.1 In these circumstances, however,
patients should not be expected to participate in randomised
comparisons, and neither should the professionals caring for them.
Department of Public Health and Policy, London School of
Hygiene and Tropical Medicine, London WC1E 7HT
Iain Chalmers
UK Cochrane Centre, Oxford OX2 7LG
time for a paradigm shift?
Diabet Med
1988;
5:
107-109[Medline].
In their overview of patient preference trials, Torgerson and
Sibbald suggest that, given the potential drawbacks of such designs,
research might usefully take the alternative approach of measuring
patient preferences within a traditional randomised controlled trials
design.1 This would conserve "the advantages of a fully
randomised design with the additional benefit of allowing for the
interaction between preference and outcome to be assessed." We used
Torgerson and Sibbald's approach to compare two schedules of routine
antenatal visits.2 Our unpublished findings on patient
preferences show how such analysis can extend and clarify trial
findings.
new style care (6-7 antenatal visits) and
traditional care (13 antenatal visits)
by the initial preferences of
the women who took part. Within each stratum we compared those
allocated to traditional and new style care for one key acceptability
outcome (dissatisfaction with the frequency of antenatal visits) and
one key outcome relating to psychosocial effectiveness (negative
attitude to the fetus). The findings are shown in the
table.
Jim Sikorski
Jennifer Wilson
Bridget Candy
Department of General Practice, United Medical and Dental
Schools of Guy's and St Thomas's Hospitals, London SE11 6SP
McPherson and Chalmers are correct that more research is
required into the interaction between preferences and outcome. Indeed,
the first randomised trial comparing an ordinary randomised trial and a
patient preference trial has just been published.1 This
trial showed no difference in recruitment and retention rates between
the two randomised segments of the trials.
Centre for Health Economics and Department of Health Studies,
University of York, York YO10 5DD
Bonnie Sibbald
National Primary Care Research and Development Centre,
University of Manchester, Manchester M13 9PL
© BMJ 1998